Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia

Journal of Bone and Mineral Research - United States
doi 10.1002/jbmr.3544
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Isolated C-Terminal Tail of FGF23 Alleviates Hypophosphatemia by Inhibiting FGF23-FGFR-Klotho Complex Formation

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia

Frontiers in Pediatrics
Child HealthPediatricsPerinatology
2020English

Commentary on “PLX-PAD Treatment of Critical Limb Ischaemia: A Clinically Effective Cell Therapy at Long Last?”

European Journal of Vascular and Endovascular Surgery
SurgeryCardiovascular MedicineCardiology
2019English

At Long Last: Olefin Metathesis Macrocyclization at High Concentration

English

At Long Last Potent and Selective KDM5 Inhibitors

Cell Chemical Biology
Molecular MedicineMolecular BiologyPharmacologyBiochemistryClinical BiochemistryDrug Discovery
2016English

Transcavernous Surgery; An Effective Treatment for Pituitary Macroadenomas

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
1995English

Nuclear Isoforms of Fibroblast Growth Factor 2 Are Novel Inducers of Hypophosphatemia via Modulation of FGF23 and KLOTHO

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2009English

Ppar Gamma Agonists: An Effective Strategy for Cancer Treatment

Journal of Pharmaceutical and Scientific Innovation
2013English

Progress at Last for Consultants

BMJ
1977English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy